The present invention is a resist material containing a repeating unit-a containing a sulfonium salt or iodonium salt of a monovalent aromatic carboxylic acid that is iodinated, is substituted or unsubstituted, and is bonded to a polymer main chain via an ester bond. This provides: a resist material having higher sensitivity and higher resolution than conventional positive resist materials, small edge roughness and size variation, and excellent pattern profile after exposure; a resist composition containing the resist material; a patterning process; and a monomer to be an ingredient for the resist material.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.

The invention relates to a novel process for the synthesis and/or purification of tetrahydrocannabinolic acid (THCA) alkanoates and/or cannabidiolic acid (CBDA) di-alkanoates. The invention also provides novel derivatives of CBDA di-alkanoates and THCA alkanoates according to Formula I, wherein R.sup.1=methyl-4-(prop-1-en-2-yl)-cyclohex-1-ene-3-yl (limonenyl); wherein R.sup.2=acetate, propionate, butyrate, or OH; wherein R.sup.3=propyl, pentyl, or heptyl; wherein R.sup.4=methyl, ethyl, or propyl; wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)cyclohex-1-ene-3-yl or methyl-4-(2-propyl)-cyclohex-5-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4=methyl, ethyl, or propyl, and wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)-cyclohex-1-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4 and R.sup.5 vanish, i.e. are radicals forming a direct bond to each other.

The invention relates to a novel process for the synthesis and/or purification of tetrahydrocannabinolic acid (THCA) alkanoates and/or cannabidiolic acid (CBDA) di-alkanoates. The invention also provides novel derivatives of CBDA di-alkanoates and THCA alkanoates according to Formula I, wherein R.sup.1=methyl-4-(prop-1-en-2-yl)-cyclohex-1-ene-3-yl (limonenyl); wherein R.sup.2=acetate, propionate, butyrate, or OH; wherein R.sup.3=propyl, pentyl, or heptyl; wherein R.sup.4=methyl, ethyl, or propyl; wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)cyclohex-1-ene-3-yl or methyl-4-(2-propyl)-cyclohex-5-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4=methyl, ethyl, or propyl, and wherein R.sup.5=methyl, ethyl, or propyl, or wherein R.sup.1=methyl-4-(2-propyl)-cyclohex-1-ene-3-yl, wherein R.sup.2O, and R.sup.1 and R.sup.2 together form a ring structure in which R.sup.2 is an internal ring atom, wherein R.sup.3=propyl, pentyl, or heptyl, wherein R.sup.4 and R.sup.5 vanish, i.e. are radicals forming a direct bond to each other.

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicy-aldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-di-chlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicy-aldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-di-chlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

Provided herein are solid forms comprising (a) 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and (b) a coformer. Pharmaceutical compositions comprising the solid forms (e.g., cocrystals) and methods for treating, preventing and managing various disorders are also disclosed.